ReviewDiscover oncology2026
Thermal modulation enhances antitumour immunity and improves immunotherapy responses in lung cancer.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lung cancer is characterised by high incidence and mortality and remains a major global health burden. Immunotherapy has advanced the treatment landscape, but its efficacy is often limited. Hyperthermia, a noninvasive treatment, offers unique potential because it not only induces tumour cell death but also modulates the immune microenvironment, enhancing systemic antitumour responses. This review discusses the immunosensitizing effects of hyperthermia in lung cancer, focusing on its ability to activate antigen presentation, enhance T-cell infiltration, and promote a shift from immunosuppressive to immune-activated tumour environments. The synergistic potential of combining hyperthermia with immunotherapy is explored, and preclinical and clinical data suggest enhanced tumour control and improved survival. Challenges in clinical translation, such as optimizing treatment schedules and standardizing parameters, are identified. This review concludes by advocating for the integration of hyperthermia with immunotherapy to improve long-term outcomes in lung cancer treatment, emphasizing the need for interdisciplinary research and personalized approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.